{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:30:39Z","timestamp":1777951839667,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep08219","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T10:33:16Z","timestamp":1422959596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: A meta-analysis"],"prefix":"10.1038","volume":"5","author":[{"given":"Zhihong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixiang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shulu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hequn","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"BFsrep08219_CR1","first-page":"333","volume":"104","author":"V Certikova-Chabova","year":"2013","unstructured":"Certikova-Chabova, V. & Tesar, V. Recent insights into the pathogenesis of nephrotic syndrome. Minerva Med 104, 333\u2013347 (2013).","journal-title":"Minerva Med"},{"key":"BFsrep08219_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy, A. A. & Symons, J. M. Nephrotic syndrome in childhood. Lancet 362, 629\u2013639 (2003).","journal-title":"Lancet"},{"key":"BFsrep08219_CR3","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s004670100021","volume":"16","author":"PA McKinney","year":"2001","unstructured":"McKinney, P. A., Feltbower, R. G., Brocklebank, J. T. & Fitzpatrick, M. M. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol 16, 1040\u20131044 (2001).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/adc.57.7.544","volume":"57","author":"O Koskimies","year":"1982","unstructured":"Koskimies, O., Vilska, J., Rapola, J. & Hallman, N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child 57, 544\u2013548 (1982).","journal-title":"Arch Dis Child"},{"key":"BFsrep08219_CR5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","volume":"8","author":"P Tarshish","year":"1997","unstructured":"Tarshish, P., Tobin, J. N., Bernstein, J. & Edelmann, C. J. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8, 769\u2013776 (1997).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep08219_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","volume":"28","author":"RM Lombel","year":"2013","unstructured":"Lombel, R. M., Gipson, D. S. & Hodson, E. M. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28, 415\u2013426 (2013).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR7","first-page":"CD002290","volume":"10","author":"N Pravitsitthikul","year":"2013","unstructured":"Pravitsitthikul, N., Willis, N. S., Hodson, E. M. & Craig, J. C. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 10, CD002290 (2013).","journal-title":"Cochrane Database Syst Rev"},{"key":"BFsrep08219_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00467-006-0264-6","volume":"22","author":"AS Abeyagunawardena","year":"2007","unstructured":"Abeyagunawardena, A. S. et al. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 22, 215\u2013221 (2007).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00467-003-1404-x","volume":"19","author":"N Prasad","year":"2004","unstructured":"Prasad, N., Gulati, S., Sharma, R. K., Singh, U. & Ahmed, M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 19, 494\u2013498 (2004).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR10","first-page":"610","volume":"22","author":"N Ueda","year":"2009","unstructured":"Ueda, N. et al. Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome. J Nephrol 22, 610\u2013615 (2009).","journal-title":"J Nephrol"},{"key":"BFsrep08219_CR11","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","volume":"27","author":"J Gellermann","year":"2012","unstructured":"Gellermann, J., Ehrich, J. H. & Querfeld, U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 27, 1970\u20131978 (2012).","journal-title":"Nephrol Dial Transplant"},{"key":"BFsrep08219_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00467-005-2080-9","volume":"21","author":"K Al-Saran","year":"2006","unstructured":"Al-Saran, K., Mirza, K., Al-Ghanam, G. & Abdelkarim, M. Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatr Nephrol 21, 201\u2013205 (2006).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrneph.2012.289","volume":"9","author":"A Sinha","year":"2013","unstructured":"Sinha, A. & Bagga, A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol 9, 154\u2013169 (2013).","journal-title":"Nat Rev Nephrol"},{"key":"BFsrep08219_CR14","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","volume":"112","author":"NJ Senff","year":"2008","unstructured":"Senff, N. J. et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112, 1600\u20131609 (2008).","journal-title":"Blood"},{"key":"BFsrep08219_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10067-010-1387-5","volume":"29","author":"E Murray","year":"2010","unstructured":"Murray, E. & Perry, M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 29, 707\u2013716 (2010).","journal-title":"Clin Rheumatol"},{"key":"BFsrep08219_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00467-014-2765-z","volume":"29","author":"K Kamei","year":"2014","unstructured":"Kamei, K. et al. Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol 29, 1181\u20137 (2014).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito, S. et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 28, 257\u2013264 (2013).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR18","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani, P. et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6, 1308\u20131315 (2011).","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFsrep08219_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti, P. et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25, 850\u2013863 (2014).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep08219_CR20","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097 (2009).","journal-title":"PLoS Med"},{"key":"BFsrep08219_CR21","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).","journal-title":"BMJ"},{"key":"BFsrep08219_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12519-014-0453-5","volume":"10","author":"L Sun","year":"2014","unstructured":"Sun, L. et al. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai. World J Pediatr 10, 59\u201363 (2014).","journal-title":"World J Pediatr"},{"key":"BFsrep08219_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito, S. et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 26, 1823\u20131828 (2011).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2215\/CJN.01180307","volume":"2","author":"P Cravedi","year":"2007","unstructured":"Cravedi, P., Ruggenenti, P., Sghirlanzoni, M. C. & Remuzzi, G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2, 932\u2013937 (2007).","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFsrep08219_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000327611","volume":"33","author":"P Cravedi","year":"2011","unstructured":"Cravedi, P. et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 33, 461\u2013468 (2011).","journal-title":"Am J Nephrol"},{"key":"BFsrep08219_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco, A. et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23, 1117\u20131124 (2012).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep08219_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima, K. et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384, 1273\u20131281 (2014).","journal-title":"Lancet"},{"key":"BFsrep08219_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00467-011-1997-4","volume":"27","author":"A Sinha","year":"2012","unstructured":"Sinha, A., Bagga, A., Gulati, A. & Hari, P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol 27, 235\u2013241 (2012).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-012-2361-z","volume":"28","author":"L Delbe-Bertin","year":"2013","unstructured":"Delbe-Bertin, L., Aoun, B., Tudorache, E., Lapillone, H. & Ulinski, T. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr Nephrol 28, 447\u2013451 (2013).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR30","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati, A. et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5, 2207\u20132212 (2010).","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFsrep08219_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000360908","volume":"39","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler, A. et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol 39, 322\u2013330 (2014).","journal-title":"Am J Nephrol"},{"key":"BFsrep08219_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00467-012-2406-3","volume":"28","author":"S Tellier","year":"2013","unstructured":"Tellier, S. et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol 28, 911\u2013918 (2013).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei, K. et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24, 1321\u20131328 (2009).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga, S. et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 25, 539\u2013544 (2010).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR35","unstructured":"Sinha, A. et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant. 29, gfu267; 10.1093\/ndt\/gfu267 (2014)."},{"key":"BFsrep08219_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11255-012-0206-0","volume":"45","author":"WY Kong","year":"2013","unstructured":"Kong, W. Y., Swaminathan, R. & Irish, A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 45, 795\u2013802 (2013).","journal-title":"Int Urol Nephrol"},{"key":"BFsrep08219_CR37","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis, V. et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23, 1269\u20131279 (2008).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR38","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00467-014-2792-9","volume":"29","author":"M Sato","year":"2014","unstructured":"Sato, M., Ito, S., Ogura, M. & Kamei, K. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome. Pediatr Nephrol 29, 1373\u20131379 (2014).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytula","year":"2010","unstructured":"Prytula, A. et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25, 461\u20138 (2010).","journal-title":"Pediatr Nephrol"},{"key":"BFsrep08219_CR40","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.4049\/jimmunol.1490027","volume":"193","author":"SH Lim","year":"2014","unstructured":"Lim, S. H. & Levy, R. Translational medicine in action: anti-CD20 therapy in lymphoma. J Immunol 193, 1519\u20131524 (2014).","journal-title":"J Immunol"},{"key":"BFsrep08219_CR41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/17474086.2014.953478","volume":"7","author":"C Rioufol","year":"2014","unstructured":"Rioufol, C. & Salles, G. Obinutuzumab for chronic lymphocytic leukemia. Expert Rev Hematol 7, 533\u2013543 (2014).","journal-title":"Expert Rev Hematol"},{"key":"BFsrep08219_CR42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CCO.0000000000000107","volume":"26","author":"AL Gagez","year":"2014","unstructured":"Gagez, A. L. & Cartron, G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol 26, 484\u2013491 (2014).","journal-title":"Curr Opin Oncol"},{"key":"BFsrep08219_CR43","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMc1308488","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu, B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 370, 1268\u201370 (2014).","journal-title":"N Engl J Med"},{"key":"BFsrep08219_CR44","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370, 1101\u20131110 (2014).","journal-title":"N Engl J Med"},{"key":"BFsrep08219_CR45","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/leu.2013.334","volume":"28","author":"A Cortelezzi","year":"2014","unstructured":"Cortelezzi, A. et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia 28, 642\u2013648 (2014).","journal-title":"Leukemia"},{"key":"BFsrep08219_CR46","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","volume":"119","author":"MS Czuczman","year":"2012","unstructured":"Czuczman, M. S. et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119, 3698\u20133704 (2012).","journal-title":"Blood"},{"key":"BFsrep08219_CR47","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","volume":"122","author":"J Radford","year":"2013","unstructured":"Radford, J. et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 122, 1137\u20131143 (2013).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep08219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep08219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep08219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:39:48Z","timestamp":1672965588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep08219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,7,15]]}},"alternative-id":["BFsrep08219"],"URL":"https:\/\/doi.org\/10.1038\/srep08219","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]},"assertion":[{"value":"19 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8219"}}